FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileStarpharma Holdings Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SPL.AX
Starpharma Holdings Limited Stock AnalysisComprehensive stock analysis for Starpharma Holdings Limited (SPL.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSPL.AX
SPL.AX
Starpharma Holdings Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SPL.AX
  1. Home
  2. Stocks
  3. Starpharma Holdings Limited

Starpharma Holdings Limited

🇦🇺SPL.AX•ASX

Starpharma Holdings Limited

🇦🇺SPL.AX•ASX

Your view on SPL.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Starpharma Holdings Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Cheryl Maley
Headquarters
4-6 Southampton Crescent, Abbotsford, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Cheryl Maley
Headquarters
4-6 Southampton Crescent, Abbotsford, VIC, AU
Description

Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis.

The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform.

This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer.

The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies.

Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Starpharma Holdings Limited. Starting points for Starpharma Holdings Limited: EPS -AUD 0.02, beta 0.75 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Starpharma Holdings Limited. Starpharma Holdings Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Starpharma Holdings Limited. Trailing twelve-month EPS for Starpharma Holdings Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Starpharma Holdings Limited. Starpharma Holdings Limited has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SPL.AX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ODTXOdyssey Therapeutics, Inc.HealthcareNASDAQ$815.2M
OGENOragenics, Inc.HealthcareAMEX$708,377
OKUROnKure Therapeutics, Inc.HealthcareNASDAQ$109.4M
OKYOOKYO Pharma LimitedHealthcareNASDAQ$56.2M
OLMAOlema Pharmaceuticals, Inc.HealthcareNASDAQ$615.0M
OMEROmeros CorporationHealthcareNASDAQ$983.7M
ONCBeOne Medicines Ltd.HealthcareNASDAQ$41.8B
ONCOOnconetix, Inc.HealthcareNASDAQ$1.0M
ONCO.NEOnco-Innovations LimitedHealthcareNEO—
ONCSQOncoSec Medical IncorporatedHealthcareOTC$596
ONCYOncolytics Biotech Inc.HealthcareNASDAQ$35.1M
ONPHOncology Pharma Inc.HealthcareOTC$109,553
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Starpharma Holdings Limited. Coverage tracks Starpharma Holdings Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Starpharma Holdings Limited.

SPL.AX AnalysisFair
Past
2
Growth
5
Health
5
Profit
1
Value
1